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ABSTRACT
Objective: Noscof tablet is a fixed dosage combination formulation having diphenhydramine (DH), ephedrine (ED), noscapine (NP), and glycerol 
glycolate (GG). A sensitive, selective, accurate, precise, and stability-indicating reversed-phase high-performance liquid chromatography (RP-HPLC) 
method with photodiode array detection has been developed and validated for simultaneous analysis of DH, ED, NP, and GG in bulk drug and Noscof 
tablets.
Methods: Reversed-phase chromatographic separation and analysis of DH, ED, NP, and GG were done on an Altima C18 column with 0.01 M KH2PO4 
buffer (pH 3.5) and acetonitrile (50:50%, v/v) as mobile phase at 0.8 ml/min flow rate in isocratic mode. Detection was performed at 260 nm. The 
method was validated in harmony with International Conference on Harmonization (ICH) guidelines. The tablet sample solution was subjected to 
diverse stress conditions using ICH strategy such as hydrolytic degradation (neutral - with distilled water, alkaline - with 2 N NaOH, and acidic - with 
2 N HCl), oxidation (with 10% H2O2), photodegradation (exposing to UV light), and dry heat degradation (exposing to 105°C).
Results: Using the above stated chromatographic conditions, sharp peaks were obtained for ED, NP, DH, and GG with retention time of 3.272 min, 
4.098 min, 5.467 min, and 6.783 min, respectively. Good regression coefficient values were obtained in the range of 2–12 µg/ml for ED, 
3.75–22.5 µg/ml for NP, 3.125–18.75 µg/ml for DH, and 25–150 µg/ml for GG. The quantification limits were 0.181 µg/ml, 0.187 µg/ml, 0.246 µg/ml, 
and 1.114 µg/ml for ED, NP, DH, and GG, respectively. The values of validation parameters are within the acceptance limits given by ICH. The ED, NP, 
DH, and GG showed more percent of degradation in acid condition and less percent of degradation in the neutral condition. The peaks of degradants 
did not interfere with the peaks of analytes. ED, NP, DH, and GG were assessed with a good percentage of the assay (near to 100%) and low percent 
relative standard deviation (<2%) in Noscof tablets using the proposed method.
Conclusion: The stability indicating RP-HPLC method developed was suitable for quantifying ED, NP, DH, and GG simultaneously in bulk as well as in 
tablet formulation.
Keywords: Noscof, Diphenhydramine, Ephedrine, Noscapine, Glycerol glycolate, Stability, Analysis.
INTRODUCTION
Combination drug therapy involves the use of ≥2 pharmaceutical agents 
given separately or as a single fixed combination dosage formulation [1]. 
This therapy is prescribed when there is no proper therapeutic 
response with monotherapy. Advantages of fixed dosage combination 
formulation include intake of few pills daily by a patient, reduction of 
medication errors, and decrease of medication costs, adverse effects of 
individual pharmaceutical agent are minimized [1-3].
Noscof tablet (manufactured by Medico Labs, Ahmadabad, India) is 
a fixed dosage combination formulation labeled to have 12.5 mg of 
diphenhydramine (DH), 8 mg of ephedrine (ED), 15 mg of noscapine 
(NP), and 100 mg of glycerol glycolate (GG) [4]. DH is a first-generation 
antihistamine [5]. ED is a central nervous system stimulant [6]. NP is an 
opium alkaloid having antitussive activity [7]. GG medication is used to 
treat diarrhea, meningitis, stroke, and encephalitis [8].
Noscof tablet is employed in the management and relief of symptoms 
of allergy, hay fever, common cold, asthma, decreased blood pressure, 
cancer of prostate, heart stroke, diarrhea, encephalitis, meningitis, 
Reye’s syndrome, and dry cough [4,9]. Noscof acts as a stimulant for the 
central nervous system. The activity of Noscof tablet involves blockage 
of histamine action, cardiac output raise, provoking vasoconstriction, 
suppression of cough reflex in brain, miniaturization of skin, and 
hydration of body. Through reducing blood vessels swelling in the nasal 
passage, Noscof expands the airway and thus improves breathing.
Our investigation is an attempt for developing and validating a reversed-
phase high-performance liquid chromatographic (RP-HPLC) method to 
quantify DH, ED, NP, and GG simultaneously in bulk and fixed dosage 
combined formulation, Noscof. As per our literature survey knowledge, 
yet no stability indicating analytical method using (RP-HPLC) technique 
using photodiode array detector (PDA) is reported for the estimation 
of DH, ED, NP, and GG simultaneously in bulk and fixed dosage 
combined formulation, Noscof. Hence, this study is aimed to develop 
a quick, simple, precise, and accurate RP-HPLC method for concurrent 
estimation of the above said drug combination in bulk and tablet 
formulation (Noscof). The developed method is validated following 
guidelines as stated by the International Conference on Harmonization 
(ICH) [10].
METHODS
Reference drugs, chemicals, and solvents
The standards of DH, ED, NP, and GG were procured from BMR chemicals 
and enterprises (Hyderabad, India). Water of HPLC grade (Milli-Q 
water, Millipore, USA) was used throughout the project. Noscof tablets 
(Medico Labs, Ahmadabad, India) consisting 12.5 mg, 8 mg, 15 mg, and 
100 mg of DH, ED, NP, and GG, respectively, were purchased and used. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i3.30942
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Acetonitrile of HPLC grade is from Merck Specialities Private Limited 
(Mumbai, India). Analytical reagent grade potassium dihydrogen 
phosphate, orthophosphoric acid, hydrochloric acid, sodium hydroxide, 
and hydrogen peroxide were purchased from Avantor Performance 
Materials India Limited (Gurgaon, India) and used in this project.
Chromatography apparatus
The simultaneous analysis of DH, ED, NP, and GG was done using 
waters HPLC system (model 2695) outfitted with quaternary pumps, 
autosampler, and PDA detector. The analysis system was examined 
using Empower 2 software.
Chromatographic condition for the analysis
For analysis and validation, Altima C18 column, 5.0 µm, 150 mm 
× 4.6 mm, with a temperature of 30°C was used. Isocratic elution 
was performed with 0.01 M potassium dihydrogen phosphate and 
acetonitrile mixture (50:50, by volume) at 0.8 ml/min flow rate. The 
mobile phase was filtered using Nylon filters (0.45 µm) and degassed 
before use. pH of 0.01 M potassium dihydrogen phosphate was adjusted 
to 3.5 with orthophosphoric acid. Eluents were detected and analyzed 
at a detection wavelength of 260 nm by injecting 10 µl volume.
Standard solutions of DH, ED, NP, and GG
Stock solution was prepared by dissolving accurately weighed 
quantities of DH (3.125 mg), ED (2 mg), NP (3.75 mg), and GG (25 mg) 
in 25 ml of diluent acetonitrile and water mixture (50:50 by volume) 
in a standard flask of capacity 25 ml. 1 ml of stock solution was diluted 
with mobile phase to make working solution with concentration 
12.5 µg/ml DH, 8 µg/ml ED, 15 µg/ml NP, and 100 µg/ml GG. Prepared 
solutions are stored (4°C) and brought back to room temperature just 
at the time of use.
Construction of DH, ED, NP, and GG calibration curves
To prepare calibration samples, appropriate aliquot volumes of stock 
solution were transferred into a series of 10 ml standard flasks then 
diluted to volume (10 ml) with mobile phase. The calibration samples 
have six concentrations of DH (3.125–18.75 µg/ml), six concentrations 
of ED (2–12 µg/ml), six concentrations of NP (3.75–22.25 µg/ml), and 
six concentrations of GG (25–150 µg/ml). The calibration samples are 
injected into Altima C18 column with a flow rate of 0.8 ml/min. The 
peak area, determined at 260 nm, of DH, ED, NP, and GG was recorded 
versus their concentration. The linearity curves of DH, ED, NP, and GG 
was constructed, and regression equations for the selected drugs were 
calculated.
Analysis of DH, ED, NP, and GG in noscof tablet
A total number of 10 Noscof tablets were powdered. Tablet powder 
equivalent to 12.5 mg of DH, 8 mg of ED, 15 mg of NP, and 100 mg 
of GG was taken into a 100 ml standard flask, 75 ml of diluent was 
added followed by sonication for 25 min. After sonication, the volume 
was made to 100 ml with diluent and filtered through a nylon filter. 
Concentration of tablet stock solution is 80 µg/ml - ED, 150 µg/ml - NP, 
125 µg/ml - DP, and 1000 µg/ml - GG. 1 ml of tablet stock solution was 
diluted to 10 ml with mobile phase in 10 ml standard flask. The final 
concentration of tablet test solution is 8 µg/ml - ED, 15 µg/ml - NP, 
12.5 µg/ml - DH, and 100 µg/ml - GG. 10 µl of the tablet test solution 
is injected into Altima C18 column with a flow rate of 0.8 ml/min for 
analysis. The peak areas of DH, ED, NP, and GG were determined. The 
concentrations of DH, ED, NP, and GG in Noscof tablet were calculated 
from the corresponding calibration curves or calculated regression 
equations.
Degradation studies
The stability tests were performed on the tablet formulation following 
the guidelines of ICH [11,12].
Oxidation
To 1 ml of tablet stock solution (80 µg/ml - ED, 150 µg/ml - NP, 
125 µg/ml - DH, and 1000 µg/ml - GG), 1 ml of 10% hydrogen peroxide 
was added. The solution was mixed and kept refluxed for 30 min at 60°C.
Acid degradation
About 1 ml of tablet stock solution (80 µg/ml - ED, 150 µg/ml - NP, 
125 µg/ml - DH, and 1000 µg/ml - GG) is mixed with 1ml of 2N 
hydrochloric acid and refluxed for 30 min at 60°C. After degradation, 
the solution was neutralized with a sufficient volume of 2N sodium 
hydroxide.
Alkali degradation
About 1 ml of tablet stock solution (80 µg/ml - ED, 150 µg/ml - NP, 
125 µg/ml - DH, and 1000 µg/ml - GG) is mixed with 1ml of 2N sodium 
hydroxide and refluxed for 30 min at 60°C. After degradation, the 
solution was neutralized with a sufficient volume of 2N hydrochloric 
acid.
Dry heat degradation
About 1 ml of tablet sample solution (80 µg/ml - ED, 150 µg/ml - NP, 
125 µg/ml - DH, and 1000 µg/ml - GG) was placed in oven at 105°C for 
6 h for dry heat degradation.
Photo stability
To study the effect of UV light on selected drug combination, 1 ml of 
tablet sample solution (80 µg/ml - ED, 150 µg/ml - NP, 125 µg/ml - DH, 
and 1000 µg/ml - GG) was exposed to UV light by placing the solution in 
UV Chamber for 7 days.
Neutral degradation
For this, 1 ml of tablet sample solution (80 µg/ml - ED, 150 µg/ml - NP, 
125 µg/ml - DH, and 1000 µg/ml - GG) was refluxed with 1 ml of water 
for 6 h at a temperature of 60°C.
In all the conditions, the degraded sample solutions were cooled to 
room temperature and diluted to 10 ml with mobile phase to obtain 
a working solution (8 µg/ml - ED, 15 µg/ml - NP, 12.5 µg/ml - DH, and 
100 µg/ml - GG) for analysis. 10 µl of the working solution was injected 
into the system. The corresponding chromatograms were recorded to 
evaluate the stability of ED, NP, DP, and GG in the applied degradation 
conditions.
RESULTS AND DISCUSSION
The current investigation considers the first RP-HPLC-PDA method 
for simultaneous estimation of ED, NP, DH, and GG. The stability of the 
selected drug combination was assessed under acid, alkali, oxidative, 
neutral, thermal, and photo conditions.
Method development
During optimization process, different columns (BDS C8, 150 mm × 
4.6 mm 5.0 µ; discovery C8, 250 mm × 4.6 mm 5.0 µ; discovery C18, 
150 mm × 4.6 mm 5.0 µ; Kromasil C18, 150 mm × 4.6 mm 5.0 µ; symmetry 
C18, 150 mm × 4.6 mm 5.0 µ; and Altima C18, 150 mm × 4.6 mm 5.0 µ), 
different organic modifiers (methanol/acetonitrile) proportions, and 
various buffers (orthophosphoric acid buffer/potassium dihydrogen 
orthophosphate buffer) with different pH values (2.5/3.5) were tried. 
As seen in Fig. 1, the good resolution and good peak shapes were 
obtained using Altima C18, 150 mm × 4.6 mm 5.0 µ as an analytical 
column with 0.01M potassium dihydrogen orthophosphate buffer, 
adjusted to pH 3.5 with orthophosphoric acid:acetonitrile (50:50 v/v) 
Fig. 1: Chromatogram showing the complete resolution of 
ephedrine, noscapine, diphenhydramine, and glycerol glycolate
507
Asian J Pharm Clin Res, Vol 12, Issue 3, 2019, 505-511
 Bhaskararao and Dannana 
as the mobile phase. For good resolution and better separation, the flow 
rate of mobile phase was adjusted to 0.8 ml/min. The chromatogram 
obtained with optimized conditions showing the separation of peaks 
due to ED, NP, DH, and GG is depicted in Fig. 1.
Method validation
The developed method is validated following guidelines as stated by 
ICH [10].
System suitability
The suitability of the system for the simultaneous analysis of ED, NP, 
DH, and GG using the proposed method is evaluated after injection of 
six replicates of the standard solutions (8 µg/ml - ED, 15 µg/ml - NP, 
12.5 µg/ml - DH, and 100 µg/ml - GG). The chromatograms were 
verified for each drug to calculate its retention time, plate count, peak 
area, peak tailing, and resolution [13]. The results revealed a %RSD of 
<1% for both peak areas and retention times. The other parameters 
of system suitability are well inside the endorsed limit. The accepted 
requirements are satisfied by this method and are shown in Table 1.
Linearity
Linearity was carried out by analyzing a series of calibration solutions 
in concentration range 2–12 µg/ml (ED), 3.75–22.5 µg/ml (NP), 
3.125–18.75 µg/ml (DH), and 25–150 µg/ml (GG). The chromatograms 
and peak area response were determined. The calibration curves 
obtained by marking peak area response of drugs versus concentration 
of drugs are presented in Fig. 2. The regression equations for ED, NP, DH, 
and GG were calculated using the corresponding calibration curve data 
(Table 2). The calibration curves, regression equations, and regression 
coefficient data revealed good linear ship between drug concentration 
and peak are a response.
Limit of detection (LOD) and limit of quantification (LOQ)
The sensitivity parameters, LOD and LOQ, for ED, NP, DH, and GG 
were established at a signal-to-noise ratio of 3:1 (LOD) and 10:1 
(LOQ). The values are shown in Table 2. The values revealed adequate 
sensitivity of the method for the simultaneous analysis of ED, NP, DH, 
and GG.
Table 1: System suitability testing parameters for the simultaneous determination of ED, NP, DH, and GG
Suitability parameter Mean value obtained for six determinations±RSD Recommended limit
ED NP DH GG
Retention time 3.396±0.761 4.215±0.500 5.654±0.461 7.214±0.878 RSD≤2
Peak area 208612±1.066 752469±0.839 697869±0.360 4717995±0.551 RSD≤2
Plate count 2460±1.397 2692±0.466 2934±0.706 3900±0.993 >2000
Resolution - 2.683±1.521 3.867±1.336 3.467±1.490 >1.5
Peak tailing 1.135±1.551 1.138±1.027 1.097±1.104 1.093±0.472 ≤2
ED: Ephedrine, NP: Noscapine, DH: Diphenhydramine, GG: Glycerol glycolate
Table 2: Linearity, regression, LOD and LOQ data for ED, NP, DH, and GG
Parameter Values obtained
ED NP DH GG
Linearity (µg/ml) 2–12 3.75–22.5 3.125–18.75 25–100
Regression equation (A=Sc+I) A=25525 c+1148 A=48451 c+7848 A=54957 c+11136 A=45046 c+79125
Regression coefficient (R2) 0.9998 0.9992 0.9994 0.9990
Slope (S) 25525 48451 54957 45046
Intercept (I) 1148 7848 11136 79125
LOD (µg/ml) 0.060 0.062 0.081 0.368
LOQ (µg/ml) 0.181 0.187 0.246 1.114
ED: Ephedrine, NP: Noscapine, DH: Diphenhydramine, GG: Glycerol glycolate, LOD: Limit of detection, LOQ: Limit of quantification
Fig. 2: Calibration curves of ephedrine, noscapine, DP, and glycerol glycolate
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Selectivity
Selectivity was carried out to check the interference due to coeluting 
peaks (from mobile phase blank and placebo) at the retention times of 
ED, NP, DH, and GG. To confirm the method selectivity, placebo solution 
and mobile phase blank were injected into the chromatography 
system. The chromatograms from the placebo and mobile phase blank 
solutions were compared with the chromatograms of standard solution 
(8 µg/ml - ED, 15 µg/ml - NP, 12.5 µg/ml - DH, and 100 µg/ml - GG) 
as well as the tablet sample solution (8 µg/ml - ED, 15 µg/ml - NP, 
12.5 µg/ml - DH, and 100 µg/ml - GG). The chromatograms in Fig. 3 
demonstrated that there are no interferences from excipients used in 
placebo and components of mobile phase at the retention time of ED, 
NP, DH, and GG. This proved the selectivity of method for ED, NP, DP, and 
GG simultaneous analysis.
Precision
Intra- and inter-day precision was demonstrated by the analysis of 
standard solution with concentration 8 µg/ml (ED), 15 µg/ml (NP), 
Table 3: Intra‑ and inter‑day precision data for ED, NP, DH, and GG
Injection No. Values obtained for intraday analysis Values obtained for interday analysis
ED NP DH GG ED NP DH GG
1 205,930 749,116 698,137 4699,457 193,700 724,380 648,381 4,525,401
2 209,230 747,827 689,205 4,700,871 194,044 705,394 648,986 4,504,576
3 207,031 753,579 694,389 4,760,524 193,500 713,665 645,913 4,510,085
4 208,029 750,061 697,222 4,763,620 191,696 718,623 653,035 4,476,993
5 209,944 746,996 695,790 4,697,301 190,553 713,349 660,628 4,487,029
6 209,922 749,053 696,849 4,699,152 192,642 723,808 659,289 4,440,562
Mean 208,348 749,439 695,265 4,720,154 192,689 716,537 652,705 4,490,774
%RSD 0.788 0.306 0.465 0.689 0.699 1.009 0.932 0.667
ED: Ephedrine, NP: Noscapine, DH: Diphenhydramine, GG: Glycerol glycolate
Table 4: Accuracy and recovery data for ED, NP, DH, and GG
Labeled 
claim (mg)
50% level 100% level 150% level
Spiked (mg) Total 
found (mg)
Assay (%) Spiked (mg) Total 
found (mg)
Assay (%) Spiked (mg) Total 
found (mg)
Assay (%)
Accuracy data of ED
8 4 11.86 98.83 8 15.82 98.85 12 19.83 99.17
8 4 11.95 99.58 8 15.91 99.45 12 19.86 99.32
8 4 11.93 99.40 8 15.91 99.44 12 19.90 99.48
Accuracy data of NP
15 7.5 22.32 99.21 15 30.13 100.45 22.5 37.24 99.31
15 7.5 22.54 100.19 15 30.22 100.74 22.5 37.20 99.20
15 7.5 22.41 99.60 15 30.25 100.85 22.5 37.41 99.75
Accuracy data of DH
12.5 6.25 18.71 99.78 12.5 25.41 101.62 18.75 31.45 100.63
12.5 6.25 18.79 100.19 12.5 25.04 100.14 18.75 31.48 100.75
12.5 6.25 18.64 99.42 12.5 25.29 101.15 18.75 31.39 100.44
Accuracy data of GG
100 50 149.68 99.78 100 198.59 99.29 150 250.56 100.22
100 50 149.71 99.81 100 200.16 100.08 150 247.52 99.01
100 50 150.38 100.25 100 199.37 99.69 150 250.25 100.10
ED: Ephedrine, NP: Noscapine, DH: Diphenhydramine, GG: Glycerol glycolate
Table 5: Percent degradation of ED, NP, DH, and GG under different stress conditions
Condition applied Peak area Degradation (%) Peak area Degradation (%)
WD AD WD AD
Degradation data of ED Degradation data of NP
Acid 208,612 196,502 5.99 752,469 700,944 7.03
Alkali 208,612 199,492 4.56 752,469 708,533 6.03
Oxidation 208,612 201,203 3.74 752,469 712,962 5.44
Dry heat 208,612 203,929 2.44 752,469 730,975 3.05
UV light 208,612 205,897 1.50 752,469 738,293 2.08
Neutral 208,612 205,976 0.51 752,469 750,236 0.50
Degradation data of DH Degradation data of GG
Acid 697,869 656,528 6.02 4,717,995 4,358,919 7.70
Alkali 697,869 658,498 5.74 4,717,995 4,464,009 5.48
Oxidation 697,869 672,627 3.71 4,717,995 4,584,918 2.92
Dry heat 697,869 677,905 2.96 4,717,995 4,592,504 2.76
UV light 697,869 690,671 1.13 4,717,995 4,659,410 1.34
Neutral 697,869 693,983 0.66 4,717,995 4,682,368 0.85
WD: Without degradation, AD: After degradation, ED: Ephedrine, NP: Noscapine, DH: Diphenhydramine, GG: Glycerol glycolate
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12.5 µg/ml (DH), and 100 µg/ml (GG) on the same day (intraday) and 
on two separate days (interday). For precision, the values of %RSD for 
intra- and inter-day variation are given in Table 3. The values were 
found to be good enough and <2%. This indicated the reproducibility 
and repeatability of the method.
Accuracy and recovery
For recovery, pre-analyzed tablet sample solution was spiked with 
pure ED, NP, DH, and GG at three concentration levels (50%, 100%, and 
150% of labeled claim). The resulting solution was analyzed 3 times 
using the propose method. For accuracy, the results were expressed 
Fig. 3: Chromatograms demonstrating method selectivity
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as percentage assay of ED, NP, DH, and GG in the samples. The overall 
results are demonstrated in Table 4, indicating the accuracy of the RP-
HPLC method developed.
Degradation study
The percent degradation of ED, NP, DH, and GG under different stress 
conditions applied is summarized in Table 5. Forced degradation study 
of tablet sample demonstrated that ED, NP, DH, and GG were more 
degraded in acid condition as compared with other applied stress 
conditions. The results also indicated that ED, NP, DH, and GG were 
observed to be more susceptible to neutral degradation condition 
than any other stress conditions. The chromatograms of degradation 
studies are shown in Fig. 4a-f. From the degradation chromatograms, 
the method specificity and stability indicating nature has proved since 
the peaks of degradation products are well resolved from the peaks of 
ED, NP, DH, and GG.
Robustness
Method robustness was determined through observing changes in the 
tailing factor, plate count, and plate count of ED, NP, DH, and GG when 
small and deliberate changes in flow rate (±1 ml/min), mobile phase 
composition (±5%), and temperature (±2°C) of the optimized method 
are made. The results are summarized in Table 6. No significant impact 
on retention time, tailing factor and plate count of ED, NP, DH, and 
GG were observed. All the values are well inside the limits and hence 
proved the method robustness.
Application of the proposed RP‑HPLC method to assay ED, NP, DH, 
and GG simultaneously in Noscof tablet
The content of ED, NP, DH, and GG in Noscof tablet was estimated using 
the developed RP-HPLC method. The results are presented in Table 7. 
The percent assay and percent relative, standard deviation values, 
showed that the developed RP-HPLC method provides a good degree of 
accuracy and reproducibility.
CONCLUSION
The developed RP-HPLC method with PDA is selective, precise, specific, 
and accurate for the quantification of ED, NP, DH, and GG simultaneously 
Table 6: Results of the effect of small changes in method conditions on system suitability values of ED, NP, DH, and GG
Parameter Value investigated PC PT Rs PC PT Rs
Robustness data of ED Robustness data of NP
Mobile phase* 45:55 2212 1.09 2581 1.13 2.5
55:45 2148 1.08 2334 1.10 2.9
Flow rate (ml/min) 0.7 2212 1.17 - 2376 1.17 2.7
0.9 3008 1.12 - 2275 1.18 2.6
Temperature (2°C) 28 2260 1.05 - 2547 1.07 2.7
32 2451 1.03 - 2629 1.06 2.7
‑ ‑ Robustness data of DH Robustness data of GG
Mobile phase* 45:55 2784 1.03 3.3 3190 1.11 2.0
55:45 2689 1.05 4.0 3149 1.06 4.4
Flow rate (ml/min) 0.7 2626 1.11 3.5 3358 1.12 2.8
0.9 2550 1.15 3.5 3283 1.12 3.1
Temperature (2°C) 28 2975 1.01 3.5 3302 1.08 2.2
32 3040 0.98 3.6 3493 1.09 2.4
*Acetonitrile and 0.01N KH2PO4 buffer ratio; PC: Plate count, PT: Peak tailing, Rs: Resolution, ED: Ephedrine, NP: Noscapine, DH: Diphenhydramine, GG: Glycerol 
glycolate
Table 7: Assay of ED, NP, DH, and GG in Noscof tablet
Drug Labeled claim (mg) Determined (mg)* Assay (%)* RSD (%)
ED 8 7.942 99.28 0.036
NP 15 14.989 99.92 0.668
DH 12.5 12.560 100.48 0.605
GG 100 99.773 99.77 0.080
*Average of three estimations, ED: Ephedrine, NP: Noscapine, DH: Diphenhydramine, GG: Glycerol glycolate
as bulk and in Noscof tablets devoid of any excipients interference. 
The method is also proved to be stability indicating one, as the peaks 
degradants formed during applied stress conditions were separated 
well from the ED, NP, DH, and GG peaks. The results obtained for the 
assay of ED, NP, DH, and GG in Noscof tablet revealed good accuracy 
and precision. Therefore, the proposed method is suitable for regular 
analysis in quality control laboratories.
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